289 related articles for article (PubMed ID: 20359580)
21. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
22. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
23. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
25. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Watanabe T
Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
28. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
29. Management of relapsed and relapsed refractory myeloma.
Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
[TBL] [Abstract][Full Text] [Related]
30. Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
[TBL] [Abstract][Full Text] [Related]
31. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
34. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
35. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
36. Pralatrexate (Folotyn) for peripheral T-cell lymphoma.
Med Lett Drugs Ther; 2010 Jul; 52(1342):55-6. PubMed ID: 20622807
[No Abstract] [Full Text] [Related]
37. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
39. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
40. Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
Cheson BD
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S3-7. PubMed ID: 18086345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
